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microcirculatory disturbances. However, the possible effects of CRP on vascular cells are 
not known. In the present investigation, the effects of CRP and hepadn derivatives on the 
release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial 
(HUVE) cells were examined. Methods: Confluent HUVE cells were resuspended and 
plated in 48 welt plate. Ceils were attached to fibronectin for 3 hours, washed and fresh 
medium with and without CRP, different LMWH or heparin molecular weight (HMW) frac- 
tions were added. TFPI released in the medium was measured using specific total TFPI 
immunoassay. Results: CRP demonstrated a potent inhibitory effect on TFPI release. In 
contrast, heparin demonstrated a potent stimulatory effect on TFPI release. The degree 
of TFPI release was shown to be dependent on the HMW distribution, with minimal to no 
effect at 3,000 dalton and maximal at 8,000-12,000 dalton. Furthermore, LMWH contain- 
ing relatively higher HMW fractions demonstrated greater potency. LMWH effectively 
reversed the inhibitory effects of CRP on TFPI release from HUVEC. These findings sup- 
port the hypothesis that CRP may play direct role in promoting hypercoaguable state that 
is correctable by LMWH. 
The Effect of CRP on TFPI Release from Human 
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1007MP-126 Oxygen Free Radicals Induce a Procoagulant State in 
Endothelial Cells by Inhibiting Tissue-Factor Pathway 
Inhibitor 
Orlando Piro, Paolo Golino, Massimo Ragni, Annalisa Scognamiglio, Giovanni Cimmino, 
Filomena Botticella, Massimo Chiadello, University Federico II, Naples, Italy 
Background: Tissue factor pathway inhibitor (TFPI) is the natural inhibitor of tissue factor 
procoagulant activity. 
Methods: To verify if oxygen free radicals (OR) may affect TFPI activity and expression, 
endothelial cells were incubated with xanthine (X, 20 mM)/xanthine oxidase (XO, 0.4 U/ 
ml) for 5 min, a system generating OR. TFPI activity was measured in supernatants by 
chromogenic assay. TFPt mRNA was analyzed by northern blot 2 and 4 hrs after OR 
exposure. Controls included unstimulated cells and cells exposed to either X or XO. To 
verify a direct effect of OR on TFPI structure and binding to Factor Xa (FXa), recombi- 
nant TFPI (5 ug) exposed to OR in vitro (X, 20 raM/XO, 0.4 U/ml), was subjected to 
Western Blot analysis and ligand dot blot analysis with filter-immobilized FXa. 
Results: TFPI activity (expressed as % of the activity of normal rabbit plasma) was 
decreased by OR exposure (3±1%) with respect to unstimulated cells; p<0.05 vs con- 
trols,n=9. X or XO alone had no effect. Northern blot showed no differences in TFPI 
mRNA levels with respect to controls. A significant degradation of TFPI exposed to OR 
with respect to controls was evident (western blot Figure A). This resulted in a decreased 
ability of TFPI binding to FXa (ligand dot blot Figure B). 
Conclusions: OR induce a procoagulant state in endothelial cells by altering TFPI struc- 
ture, resulting in inhibition of TFPI binding to Factor Xa and loss of activity. This phenom- 
enon might have important consequences during reperfusion of post-ischemic 
myocardium. 
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logical Method. Von Willebrand factor antigen (ELISA) and fibdnolytic potential 
(plasminogen activator inhibitor (PAl-l) antigen and tPA antigen), were also assessed. 
During follow-up (median 7 years), 197 patients had a first cardiovascular event (nonfatal 
MI, cardiac death, stroke, angina or congestive heart failure). Risk ratios (RR) versus 
lowest quartile were determined by multivariate Cox models, adjusting for age, hyperten- 
sion, diabetes, smoking and total cholesterol. Higher levels of Fibrinogen (FIF) and von 
Willebrend Factor, and PAl-1 and tPA antigen were associated with significantly 
increased CVD events. 
Conclusion: In a prospective evaluation of Framingham subjects with no prior clinical 
CVD, higher levels of prothrombotic factors - Fibrinogen and Von Willebrand Factor and 
impaired fibrinolytic potential (increased PAl-1 and tPA antigen) confer increased CVD 
risk. Measurement of these factors may improve risk assessment and facilitate selection 
of individuals for preventive therapy with the increasing number of effective anti-throm- 
botic agents. 
Comparison of highest to lowest quartile 
RR (95% CI) p-value 
Fibrinogen (FIF) 2.05 (1.15-3.65) 0.01 
Fibrinogen (Clauss) 1,14 (0.72-1.81) 0.57 
PAl-1 antigen 1.76 (1.09-2.90) 0.02 
tPA antigen 2.08 (t ,19-3.62) 0.01 
vWF antigen 1.57 (1.01-2,43) 0.04 
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1007MP-127 HemostaUc Predictors of Cardiovascular Disease: 
Prospective Evaluation of the Framingham Offspring 
Study 
Geoffrey H. Toiler, Joseph Massaro, James E. Muller, Daniel Levy, Murray A. Mittleman, 
Izabela Lipinska, DaLi Feng, Christopher O'Donnell, Peter W. Wilson, Ralph B. 
D/~gostino, Royal North Shore Hospital, Sydney, Australia, Boston University School of 
Medicine, Boston, Massachusetts. 
Background: Since thrombosis plays a major role in cardiovascular disease (CVD), we 
determined whether hemostatic factors predicted future CVD events in subjects with no 
pdor known CVD. 
Methods: We prospectively studied 3213 subjects (mean age 54 years, 55% 
females)from the Offspdng Cohort of the Framingham Heart Study. Fibrinogen was mea- 
sured by the Clauss functional assay and the Functional Intact Fibdnogen (FIF)lmmuno- 
1007MP-128 Attenuation of Migration of Vascular Smooth Muscle 
Cells by Overexpression of Plasminogen Activator 
Inhibitor Type 1 
Michael G. Haves, Burton E. Sobel, Douglas J. Taatjes, Mercedes Rincon, David J. 
Schneider, University of Vermont, Burlington, Vermont. 
Background: Acute coronary syndromes are generally precipitated by rupture of vulner- 
able plaques. A thin, relatively acellular cap overlaying a necrotic lipid core characterizes 
vulnerable plaques. We have implicated ecreased vascular smooth muscle cell (VSMC) 
migration as one factor predisposing to plaque vulnerability. Elevated arterial content of 
plasminogen activator inhibitor type-1 (PAl-l) has been associated with increased dsk of 
plaque rupture. VSMC migration depends on cell surface expression of ptasminogen 
activators. PAl-1 is the pdmary physiologic inhibitor of plasminogen activators. Thus, we 
sought to determine whether increased expression of PAl-1 decreases VSMC migration. 
Methods: Constitutive, VSMC-specific overexpression of PAl-1 was induced in trans- 
genic mice with the use of the SM22(x promoter. VSMC migration was characterized in a 
well - insert micropore system. Matrigel was used as the extrecellular matrix (2 ~m thick- 
ness) and rat platelet-derived growth factor-BB was used as a chemoattractant. Migra- 
tion was quantified with laser scanning cytometry. 
Results: Immunohistochemical analysis of aortic tissue demonstrated increased PAl-1 in 
transgene positive mice compared with transgene negative Uttermates. VSMC (50,000 
cells) were seeded and migration through Matdgel was quantified after 20 hours. Migra- 
tion was consistently attenuated with transgene positive VSMC (4,459 ± 1313 [SD] 
VSMC from transgene positive mice and 7,323 ± 822 VSMC from transgene negative 
mice, p=0.03). Similar significant differences were seen with cells from 3 pairs of litter. 
mates. 
Conclusion: Thus, selective overexpression of PAl-1 in VSMC attenuates their migration 
and may potentiate volution of VSMC-poor atherosclerotic plaques that are particularly 
prone to rupture. 
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1007MP-129 Transforming Growth Factor-b Regulation of 
Plasminogen Activator Inhibitor-1 Gene Expression at 
the 4G/5G Polymorphism 
John A. Schoenhard, Douglas E. Vaughan, Vanderbilt University Medical Center, 
Nashville, Tennessee. 
Background: Clinical studies have demonstrated that circulating levels of plasminogen 
activator inhibitor-1 (PAl-l) are strongly influenced by genotype at an insertion / deletion 
polymorphism describing alleles containing either four or five sequential guanine bases 
(4G or 5G, respectively) at -575 bp in the PAl-1 promoter. However, the molecular mech- 
anisms underlying allele-selective regulation of PAI*I expression remain poorly under- 
stood. We studied the mechanisms by which transforming growth tactor-~ (TGF-~,) 
regulates PAl-1 expression at the site of the 4G / 5G polymorphism. 
Methods: Transcdptional activation was assessed using PAl-1 promoter (-804 to +76 bp) 
/ luciferase reporter constructs in transfected HepG2 cells. 
Results: TGF-~ induced PAl-1 promoter activity independent of genotype (4G vs. 5G: 
14.2- vs. 13.4-fold at 250 pM TGF-I~; EC50 = 11.2 vs. 9.9 pM TGF-~). Although two 
Smad-binding elements flank the 4G / 5G polymorphism, neither Smad3.nor Smad4 
overexpression yielded allele-selective regulation of PAl-1 promoter activity. Rather, 
Smad3 induced the 4G allele by 9.7-fold and the 5G allele by 8.9-fold, while Smad4 
induced both alleles by 2.9-fold. TGF-~ treatment following Smad4 overexpression 
induced both alleles by 5.8-fold, but had no effect on Smad3-induced expression. Muta- 
tion of the PAl-1 promoter's proximal E-box (-569 to -564 bp) reduced TGF-13, Smad3, 
and Smad4 mediated induction of both 4G and 5G alleles by more than 50% by prevent- 
ing synergistic interactions between activated Smads and E-box binding bHLH transcrip- 
tion factors such as TFE3. However, no such effects were observed following mutation of 
the E-box which overlaps the 4G / 5G polymorphism. 
Conclusion: These results confirm that TGF-13 strongly induces PAl-1 promoter activity 
